Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Expanding the Clinical Utility of Rapid Genome Sequencing in Pediatric Epilepsy
EF 2023-24
Résumé
Epilepsy is a brain condition where people have unpredictable and repeated seizures. Roughly 300,000 Canadians have epilepsy, and it often emerges within the first year of life. For many babies with epilepsy, their condition is related to their genetic code. Finding the genetic causes early can help doctors quickly provide treatments that are more tailored to each baby’s specific needs. Rapid genome sequencing (rGS) is a promising new technology capable of decoding a person's entire genetic information in a few days. Our team pioneered its use for babies with epilepsy, but the scope of our pilot was limited by only looking for certain subsets of genetic variants. Many babies are still left without a diagnosis, and some of the information generated from rGS is underused and understudied. Our study aims to use existing data from rGS to explore innovative ways of analyzing genes related to epilepsy. We will expand the use of rGS by uncovering more rare and complicated genetic variants that are often missed by standard tests. We will also create a score that can predict the likelihood of babies having epilepsy by looking at common changes within the DNA. Finally, people with epilepsy can have dangerous reactions to epilepsy medicines. We will use rGS to provide genetic information that can help doctors choose the right medication at the right dosage to keep epilepsy patients safe. The results of our research will not only benefit the participating babies with epilepsy, but will also offer valuable guidance to policymakers, funding agencies, and healthcare providers as they shape the standard of care for childhood epilepsy. This study is a step towards a more effective and personalized approach for diagnosing and managing epilepsy in its earliest stage.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506391
Name
Nguyen Jimmy N
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Expanding the Clinical Utility of Rapid Genome Sequencing in Pediatric Epilepsy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Epilepsy; Genetics; Genome Sequencing; Genomics; Mitochondrial Disorder; Neurodevelopmental Disorder; Pharmacogenetics; Polygenic Risk Score; Rapid Genome Sequencing; Tandem Repeat Expansion
Abstract
Epilepsy is a brain condition where people have unpredictable and repeated seizures. Roughly 300,000 Canadians have epilepsy, and it often emerges within the first year of life. For many babies with epilepsy, their condition is related to their genetic code. Finding the genetic causes early can help doctors quickly provide treatments that are more tailored to each baby’s specific needs. Rapid genome sequencing (rGS) is a promising new technology capable of decoding a person's entire genetic information in a few days. Our team pioneered its use for babies with epilepsy, but the scope of our pilot was limited by only looking for certain subsets of genetic variants. Many babies are still left without a diagnosis, and some of the information generated from rGS is underused and understudied. Our study aims to use existing data from rGS to explore innovative ways of analyzing genes related to epilepsy. We will expand the use of rGS by uncovering more rare and complicated genetic variants that are often missed by standard tests. We will also create a score that can predict the likelihood of babies having epilepsy by looking at common changes within the DNA. Finally, people with epilepsy can have dangerous reactions to epilepsy medicines. We will use rGS to provide genetic information that can help doctors choose the right medication at the right dosage to keep epilepsy patients safe. The results of our research will not only benefit the participating babies with epilepsy, but will also offer valuable guidance to policymakers, funding agencies, and healthcare providers as they shape the standard of care for childhood epilepsy. This study is a step towards a more effective and personalized approach for diagnosing and managing epilepsy in its earliest stage.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nguyen, Jimmy N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~